Advancing findings surround the compound, a double agonist for GLP-1 and GIP, demonstrate promising possibility in managing obesity and related disease conditions. Early clinical trials suggest substantial weight loss https://retatrutideresearchlab.co.uk/product/ozempic-025-mg-peptide/